Lumida
/BVS
⌘K
Bioventus Inc

Bioventus Inc

BVS
$13.06USD-4.18%-0.57 today

MARKET CAP

1.1B

P/E (TTM)

17.9x

FWD P/E

17.0x

DAY RANGE

$13 – $14

52W RANGE

$6
$16

AI Summary

Stalk
Sell NowMedium

The BVS stock is in a Stage 3 distribution phase, forming lower highs and lower lows beneath declining EMAs, signaling medium-term bearish bias. Short-term price is tightly tracking below the 9 and 20 EMAs with neutral OB/OS, offering a favorable selling opportunity into the EMA and 50 DMA zone. Long-term uptrend remains intact above the 200 DMA, but resistance overhead and weakening momentum support a sell now posture.

  • Q2 net sales $153M (+4% YoY) fueled by 11.5% pain treatments growth.
  • HA franchise outperformed expectations, funding PRP and PNS investments.
  • Gross margin fell 90bps YoY to 75%, reflecting cost pressures.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$430.9M$512.1M$512.3M$573.3M$568.1M
YoY %+18.8%+0.0%+11.9%-0.9%
P / Sales1.5x0.3x0.6x1.2x0.9x
EV / Sales3.0x2.1x1.7x2.1x1.6x
Gross Profit, Adj.$302.7M$331.1M$328.2M$388.2M$388.2M
YoY %+9.4%-0.9%+18.3%-0.0%
Margin %70.3%64.6%64.1%67.7%68.3%
EV / Gross Profit4.3x3.3x2.7x3.0x2.4x
EBITDA, Adj.$55.9M$20.7M$58.7M$71.0M$103.3M
YoY %-62.9%+182.9%+20.9%+45.6%
Margin %13.0%4.1%11.5%12.4%18.2%
EV / EBITDA23.4x52.6x15.0x16.6x8.9x
EBIT$12.1M$-42.5M$467,000$21.5M$54.1M
YoY %-452.7%+101.1%+4494.0%+152.0%
Margin %2.8%-8.3%0.1%3.7%9.5%
EV / EBIT108.4x-25.6x1888.1x54.9x17.0x
Net Income$-6.6M$-158.7M$-156.2M$-36.1M$22.7M
YoY %-2303.9%+1.6%+76.9%+162.9%
Net Margin-1.5%-31.0%-30.5%-6.3%4.0%
EPS (GAAP)-$0.15-$2.59-$2.49-$0.56$0.33
YoY %-1626.7%+3.9%+77.5%+158.9%